[Customer Login]

In a separate press release issued today, the Company announced the sale of its Therapist Helper business for US$12.3 million

Markham, ON - Nightingale Informatix Corporation (“Nightingale” or the “Company”) (TSX-V: NGH), one of North America’s fastest growing healthcare software and services providers, announces its financial results for the three- and nine-month periods ended December 31, 2007. All results are reported in Canadian dollars unless otherwise stated.

In a separate press release issued earlier today, Nightingale announced the US$12.3 million sale of its Therapist Helper business to Netsmart Technologies, Inc. As a result of this transaction, Nightingale’s financial results for the three- and nine-month periods exclude contribution from the Therapist Helper business, and are reported as continuing operations. This transaction materially improves the Company’s balance sheet.

Q3 Fiscal 2008 Financial Summary

- Revenue from continuing operations (excluding Therapist Helper business) was $3.9 million, compared to $4.2 million in Q3 fiscal 2007.

- Including contribution from the Therapist Helper business, revenue would have been $5.1 million in Q3 fiscal 2008.

- Change in the value of the US dollar is estimated to have negatively affected Q3 revenue by approximately 14%, or $0.5 million, versus the comparable period in fiscal 2007.

- Recurring revenue(1a) increased to $3.2 million, or 82% of total revenue, compared to $2.3 million, or 56% of total revenue, in Q3 fiscal 2007.

- Adjusted EBITDA(1b) (earnings before interest, taxes, depreciation, amortization and stock based compensation) was $(1.8) million, compared to adjusted EBITDA of $(0.01) million in Q3 fiscal 2007.

- Net loss from continuing operations was $3.5 million, or $(0.05) per share, compared to net loss of $0.3 million, or $(0.01) per share, in Q3 fiscal 2007.

- Deferred revenue has increased to $5.6 million at December 31, 2007, compared to $3.5 million at March 31, 2007.

- Upon completion of the sale of the Therapist Helper business, Nightingale will strengthen its balance sheet by adding to its cash balance and paying down a portion of its debt.

“Operationally, in Q3 we achieved a significant milestone with our OntarioMD contract win; however, our financial performance in the quarter fell below our expectations,” said Sam Chebib, President & CEO Nightingale Informatix Corporation. “Overall, results were affected by a delay in funding initiatives in certain jurisdictions, which impacted software license sales, and the negative year-over-year fluctuation in foreign exchange rates. In addition, our contract with OntarioMD had an impact on our Q3 revenue from the province of Ontario because many potential clients are delaying their purchase decision until we have completed the certification process. We expect these deferred sales opportunities to materialize in future periods and look forward to strong contribution from OntarioMD in fiscal 2009.”

Mr. Chebib continued: “Looking forward, while Q3 was a challenging quarter, we believe we have established an operating platform and strong market position with the right technology, strategy and personnel to drive growth over the long-term. Through our OntarioMD contract win and, more recently, the agreement with the Medical Society of the State of New York, we are steadily building our pipeline, and we have demonstrated our ability to win sizable and highly competitive EMR mandates across North America. With the changes we made to our sales team subsequent to quarter-end, we believe we are now better positioned to address the unique needs of the U.S. and Canadian healthcare industries, convert our pipeline of opportunities into sales and grow the number of healthcare practitioners on our EMR platform.”

Recent Operational Highlights

- Signed a 15-year contract with OntarioMD to be one of three funding approved ASP EMR providers. Currently, there is total funding of $28,600 per physician for 2,700 of Ontario’s 22,000 physicians, with additional funding expected to become available.

- Signed a three-year US$3.1 million revenue cycle management agreement with Baltimore, Maryland-based Harbor Hospital.

- Appointed Michael Ford as Chief Financial Officer and Nick Vaney as VP, Operations and Chief Strategy Officer.

- Subsequent to quarter end, announced additional annual cost-saving synergies of approximately $1.6 million, resulting from the VantageMed acquisition and the creation of a streamlined and geographically focused sales team.

- Subsequent to quarter end, signed a three-year agreement with the Medical Society of the Sate of New York (MSSNY) to be one of three preferred ASP EMR providers for MSSNY’s 30,000 members.

Q3 and Year-to-date Fiscal 2008 Financial Review
As previously stated, all financial results for the three- and nine-month periods ended December 31, 2007, are reported as continuing operations.

Revenue from continuing operations for Q3 fiscal 2008 was $3.9 million, compared to revenue of $4.2 million in Q3 fiscal 2007. The year-over-year decline was a result of lower software license sales during the quarter, the negative impact of the fluctuation in foreign exchange rates and timing of revenue recognition associated with the Company’s Harbor Hospital contract, as Nightingale commenced work during the quarter, but did not record any corresponding revenue. For the year-to-date period, revenue from continuing operations was $14.7 million, a 39% increase over the corresponding period in fiscal 2007.

Recurring revenue, consisting of software support and maintenance, utilization fees, transaction fees, data management, transcription and billing services, was $3.2 million, or approximately 82% of total revenue, for Q3 fiscal 2008. For the year-to-date period, recurring revenue was $9.8 million or 67% of total revenue.

In Q3 fiscal 2008, Nightingale generated approximately 78% of its revenue in the U.S. As such, the Company estimates that revenue was negatively affected by U.S. currency fluctuations relative to the Canadian dollar by a difference of approximately 14%, or $0.5 million. Nightingale generates 51% of its expenses (including costs of goods sold) in the U.S., providing the Company with a natural hedge position. However, going forward, Nightingale expects to generate an increasing percentage of revenue in the U.S. and will therefore continue to be susceptible to currency exchange fluctuations over the coming quarters.

In Q3 fiscal 2008, gross profit margin decreased to 67%, compared to 73% in Q3 fiscal 2007, primarily as a result of a reduction in higher margin software sales during the quarter. For the year-to-date period, gross profit margin was 73%, up from 69% for the same period last year.

Nightingale generated adjusted EBITDA of $(1.8) million in Q3 fiscal 2008, compared to adjusted EBITDA of $(0.01) million in Q3 fiscal 2007. The year-over-year decrease in adjusted EBITDA was due to a combination of factors, which included: lower software sales, a negative impact from the reduction in value of the US dollar relative to the Canadian dollar, the timing of revenue recognition associated with the Company’s Harbor Hospital contract and increased investment in infrastructure to support future growth. For the year-to-date period, Nightingale generated adjusted EBITDA of $(2.3) million, compared to adjusted EBITDA of $(2.2) million for the same period in fiscal 2007.

Loss from continuing operations was $3.5 million, or $(0.05) per share, compared to a net loss of $0.3 million or $(0.01) per share in Q3 fiscal 2007. For the year-to-date period, loss from continuing operations was $7.2 million, or $(0.11) per share, compared to a net loss of $3.8 million, or $(0.10) per share for the same period last year.

A full set of financial statements and MD&A will be available at http://www.nightingale.md and www.sedar.com .

(1)Non-GAAP Financial Measures
The Company internally measures its performance and results of initiatives through a number of measures that are not recognized under Canadian generally accepted accounting principles (GAAP) and may not be comparable to similar measures used by other companies.

a. Recurring and Non-Recurring Revenue
The Company has included recurring revenue and non-recurring revenue measurements since it believes that this information would be useful to investors to help evaluate its performance. Investors should be cautioned, however, that recurring revenue and non-recurring revenue should not be construed as an alternative to revenue as determined in accordance with GAAP.

b. Adjusted EBITDA
The Company has included an adjusted EBITDA measurement since it believes that this information would be useful to investors to help evaluate the performance of the Company. Investors should be cautioned, however, that adjusted EBITDA should not be construed as an alternative to net earnings as determined in accordance with GAAP. The Company's method of calculating adjusted EBITDA may differ from the methods used by other companies and, accordingly, it may not be comparable to similarly titled measures used by other companies.

Adjusted EBITDA is a non-GAAP measure that management believes is a useful supplemental measure of operating performance prior to other loss (income), interest, income taxes, depreciation, amortization, and stock-based compensation. Management believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance, and Management uses this information internally for forecasting and budgeting purposes.

The following provides a reconciliation of Adjusted EBITDA to Net Income/ Loss:

Name	Definition	Fiscal Quarter Ended December 31, 2007	Fiscal Quarter Ended December 31, 2006	Nine Months Ended December 31, 2007	Nine Months Ended December 31, 2007
Adjusted EBITDA	Net Income(Loss)	$(3,536,270)	$(352,250)	$(7,233,615)	$(3,757,506)
	Adjustments for:
	Other Loss (Income)	16,646	-40,858	169,649	-157,721
	Interest	719,569	40,511	1,868,387	594,108
	Depreciation and Amortization	759,768	214,759	2,345,364	609,076
	Stock-based Compensation	241,111	126,264	512,078	506,442
	Adjusted EBITDA (Loss)	$(1,799,176)	$(11,574)	$(2,338,137)	$(2,205,601)

Notice of Conference Call and Webcast
Nightingale will host a conference call Monday March 3, 2008, at 8:30 a.m. Eastern Standard Time. To access the conference call by telephone, dial 416-644-3422 or 1-800-731-5319. Please connect approximately fifteen minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until March 10, 2008. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter reference number 21262891#.

A live audio webcast of the call will be available at www.newswire.ca and http://www.nightingale.md . Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be necessary. The webcast will be archived for 365 days.

About Nightingale
Nightingale is one of the fastest growing health care service and software companies in North America with over 4.7 million patient records under management in a hosted (ASP) environment. It is recognized as an industry leader in Web-based clinician and community based electronic medical records (EMR) serving the needs of small primary care practices, multi-physician outpatient clinics, and large scale regional health organizations and networks. Coupled with integrated practice management, transcription and revenue cycle management, Nightingale’s comprehensive service offering allows customers to enhance patient care, increase revenue opportunities and optimize operations. Nightingale is continuously innovating and enhancing its services to meet the needs of its growing and diverse customer base. Nightingale – Healthcare connected. www.nightingale.md

For further information, contact:

Michael Ford CFO Nightingale Informatix Corporation Tel: 905-307-7870 mford@nightingale.md

Dave Mason Investor Relations The Equicom Group Tel: 416-815-0700 x237 Email: dmason@equicomgroup.com

Forward Looking Statement

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this releas.